Second NRF2 Degrader Enters Clinical Development: Nutshell Therapeutics' NTS231 Received FDA IND Clearance

RegulatoryapprovedNTS231Positive

AI Analysis

Summary

Nutshell Therapeutics announced FDA IND clearance for NTS231, a covalent allosteric NRF2 degrader, marking the second NRF2 degrader to enter clinical development. The company focuses on AI-driven allosteric drug discovery.

Clinical Trial Data

Phase

Phase 1

Outcome Details

FDA IND clearance received

Importance:6/10

Sentiment:

0.70

NRF2 degraderallosteric drugmolecular glueIND clearanceAI-driven discovery

Related Companies

$MOLN

Read the original article

Published by PR Newswire Biotech on September 25, 2026 12:00 PM

Read Original